Influence of phenotype at diagnosis and of other potential prognostic factors on the course of inflammatory bowel disease

American Journal of Gastroenterology

Volumn 104, Issue 2, 2009, Pages 371-383

  Romberg Camps, M J L ^a,c   Dagnelie, P C ^b   Kester, A D M ^b   Hesselink Van De Kruijs, M A M ^a   Cilissen, M ^a   Engels, L G J B ^c   Van Deursen, C ^c   Hameeteman, W H A ^a   Wolters, F L ^d   Russel, M G V M ^e   Stockbrugger R W ^a  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MAASTRICHT UNIVERSITY   (Netherlands)

^c Sittard Geleen Heerlen   (Netherlands)

^d Department of Obstetrics and Gynaecology   (Netherlands)

^e MEDISCH SPECTRUM TWENTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; SALAZOSULFAPYRIDINE; STEROID; TIOGUANINE;

ARTICLE; CIGARETTE SMOKING; COLON RESECTION; CROHN DISEASE; DISEASE COURSE; DISEASE SEVERITY; ENTERITIS; FAMILY HISTORY; FOLLOW UP; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MAJOR CLINICAL STUDY; PHENOTYPE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; QUESTIONNAIRE; RECURRENT DISEASE; RISK FACTOR; SMOKING CESSATION; TREATMENT INDICATION; TREATMENT OUTCOME; ULCERATIVE COLITIS;

ADOLESCENT; ADULT; AGE FACTORS; AGED; CHILD; CHILD, PRESCHOOL; COLITIS, ULCERATIVE; CROHN DISEASE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; MIDDLE AGED; PHENOTYPE; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RECURRENCE; RISK FACTORS; SEX FACTORS; YOUNG ADULT;

EID: 59749102408     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2008.38     Document Type: Article

References (54)

1. Sartor RB. Pathogenesis and immune mechanisms of chronic inflammatory bowel diseases. Am J Gastroenterol 1997;92:5S-11S.
2. Russel MG, Dorant E, Volovics A et al. High incidence of inflammatory bowel disease in the Netherlands: results of a prospective study. The South Limburg IBD Study Group. Dis Colon Rectum 1998;41:33-40.
3. Shivananda S, Lennard Jones J, Logan R et al. Incidence of inflammatory bowel disease across Europe: is there a difference between north and south? Results of the European Collaborative Study on inflammatory Bowel Disease (EC-IBD). Gut 1996;39:690-7.
4. Russel MG. Changes in the incidence of inflammatory bowel disease: what does it mean? Eur J Intern Med 2000;11:191-6.
5. Loftus EV Jr. Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences. Gastroenterology 2004;126:1504-17.
6. Joossens S, Reinisch W, Vermeire S et al. The value of serologic markers in indeterminate colitis: a prospective follow-up study. Gastroenterology 2002;122:1242-7.
7. Boonen A, Dagnelie PC, Feleus A et al. The impact of inflammatory bowel disease on labor force participation: results of a population sampled case-control study. Inflamm Bowel Dis 2002;8:382-9.
8. Stark R, Konig HH, Leidl R. Costs of inflammatory bowel disease in Germany. Pharmacoeconomics 2006;24:797-814.
9. Bassi A, Dodd S, Williamson P et al. Cost of illness of inflammatory bowel disease in the UK: a single centre retrospective study. Gut 2004;53:1471-8.
10. Munkholm P, Langholz E, Davidsen M et al. Disease activity courses in a regional cohort of Crohn's disease patients. Scand J Gastroenterol 1995;30:699-706.
11. Moum B, Ekbom A, Vatn MH et al. Clinical course during the 1st year after diagnosis in ulcerative colitis and Crohn's disease. Results of a large, prospective population-based study in southeastern Norway, 1990-93. Scand J Gastroenterol 1997;32:1005-12.
12. Oostenbrug LE, van Dullemen HM, te Meerman GJ et al. Clinical outcome of Crohn's disease according to the Vienna classification: disease location is a useful predictor of disease course. Eur J Gastroenterol Hepatol 2006;18:255-61.
13. Veloso FT, Ferreira JT, Barros L et al. Clinical outcome of Crohn's disease: analysis according to the vienna classification and clinical activity. Inflamm Bowel Dis 2001;7:306-13.
14. Henriksen M, Jahnsen J, Lygren I et al. Clinical course in Crohn's disease: results of a five-year population-based follow-up study (the IBSEN study). Scand J Gastroenterol 2007;42:602-10.
15. Henriksen M, Jahnsen J, Lygren I et al. Ulcerative colitis and clinical course: results of a 5-year population-based follow-up study (the IBSEN study). Inflamm Bowel Dis 2006;12:543-50.
16. Wolters FL, Russel MG, Sijbrandij J et al. Phenotype at diagnosis predicts recurrence rates in Crohn's disease. Gut 2006;55:1124-30.
17. Lakatos PL, Szalay F, Tulassay Z et al. Clinical presentation of Crohn's disease. association between familial disease, smoking, disease phenotype, extraintestinal manifestations and need for surgery. Hepatogastroenterology 2005;52:817-22.
18. Baert F, Caprilli R, Angelucci E. Medical therapy for Crohn's disease: top-down or step-up? Dig Dis 2007;25:260-6.
19. Russel M. Incidence, risk factors and quality of life in IBD. PhD Thesis. Data management of the South Limburg inflammatory Bowel Disease Registry, South Limburg, 1997, 49-57.
20. StatLine: 〈http://statline.cbs.nl/StatWeb/start.asp?lp=Search/ Search〉.
21. Lennard Jones JE. Classification of inflammatory bowel disease. Scand J Gastroenterol 1989;170:2-6.
22. Gasche C, Scholmerich J, Brynskov J et al. A simple classification of Crohn's disease: report of the Working Party for the World Congresses of Gastroenterology, Vienna 1998. Inflamm Bowel Dis 2000;6:8-15.
23. Hoie O, Wolters F, Riis L et al. Ulcerative colitis: patient characteristics may predict 10-yr disease recurrence in a European-wide population-based cohort. Am J Gastroenterol 2007;102:1692-701.
24. Grambsch PM, Therneau TM. Proportional hazards test and diagnostics based on weighted residuals. Biometrica 1994;81:515-26.
25. Statacorp. Stata Statistical Software: Release 8.2. Stata Corporation: College Station, TX, 2005.
26. Shivananda S, Hordijk ML, Pena AS et al. Crohn's disease: risk of recurrence and reoperation in a defined population. Gut 1989;30:990-5.
27. Agrez MV, Valente RM, Pierce W et al. Surgical history of Crohn's disease in a well-defined population. Mayo Clinic Proc 1982;57:747-52
28. D ' Haens G, Rutgeerts P. Postoperative recurrence of Crohn's disease: pathophysiology and prevention. Inflamm Bowel Dis 1999;5:295-303.
29. Nemetz A, Molnar T, Zagoni T et al. Phenotypes defined by the "Vienna Classification" in 100 Hungarian patients with Crohn's disease. Rev Esp Enferm Dig 2003;95:533-538, 27-33.
30. Hofer B, Bottger T, Hernandez-Richter T et al. The impact of clinical types of disease manifestation on the risk of early postoperative recurrence in Crohn's disease. Hepatogastroenterology 2001;48:152-5.
31. Bernell O, Lapidus A, Hellers G. Risk factors for surgery and postoperative recurrence in Crohn's disease. Ann surg 2000;231:38-45.
32. Aeberhard P, Berchtold W, Riedtmann HJ et al. Surgical recurrence of perforating and nonperforating Crohn's disease. A study of 101 surgically treated Patients. Dis Colon Rectum 1996;39:80-7.
33. Sugita A, Fukushima T, Yamazaki Y et al. [Postoperative recurrence form of Crohn's disease: comparison between perforating and non perforating types]. Nippon Geka Gakkai Zasshi 1993;94:114-8.
34. Greenstein AJ, Lachman P, Sachar DB et al. Perforating and non-perforating indications for repeated operations in Crohn's disease: evidence for two clinical forms. Gut 1988;29:588-92.
35. Hamon JF, Carbonnel F, Beaugerie L et al. [Comparison of long-term course of perforating and non-perforating Crohn disease]. Gastroenterol Clin Biol 1998;22:601-6.
36. Rutgeerts PJ. Conventional treatment of Crohn's disease: objectives and outcomes. Inflamm Bowel Dis 2001;7 (Suppl 1):S2-8.
37. Hanauer SB, Present DH. The state of the art in the management of inflammatory bowel disease. Rev Gastroenterol Disord 2003;3:81-92.
38. Bianchi Porro G, Cassinotti A, Ferrara E et al. Review article: the management of steroid dependency in ulcerative colitis. Aliment Pharmacol Ther 2007;26:779-94.
39. Feagan BG. Maintenance therapy for inflammatory bowel disease. Am J Gastroenterol 2003;98:S6-17.
40. Lakatos PL, Szamosi T, Lakatos L. Smoking in inflammatory bowel diseases: good, bad or ugly? World J Gastroenterol 2007;13:6134-9.
41. Langholz E, Munkholm P, Davidsen M et al. Course of ulcerative colitis: analysis of changes in disease activity over years. Gastroenterology 1994;107:3-11.
42. Hoie O, Wolters FL, Riis L et al. Low colectomy rates in ulcerative colitis in an unselected European cohort followed for 10 years. Gastroenterology 2007;132:507-15.
43. Leijonmarck CE, Persson PG, Hellers G. Factors affecting colectomy rate in ulcerative colitis: an epidemiologic study. Gut 1990;31:329-33.
44. Langholz E, Munkholm P, Davidsen M et al. Colorectal cancer risk and mortality in patients with ulcerative colitis. Gastroenterology 1992;103:1444-51.
45. Farmer RG, Easley KA, Rankin GB. Clinical patterns, natural history, and progression of ulcerative colitis. A long-term follow-up of 1116 patients. Dig Dis Sci 1993;38:1137-46.
46. Edwards FC, Truelove SC. The course and prognosis of ulcerative colitis. Gut 1963;4:299-315.
47. Hendriksen C, Kreiner S, Binder V. Long term prognosis in ulcerative colitis - based on results from a regional patient group from the county of Copenhagen. Gut 1985;26:158-63.
48. Stewenius J, Adnerhill I, Ekelund GR et al. Risk of relapse in new cases of ulcerative colitis and indeterminate colitis. Dis Colon Rectum 1996;39:1019-25.
49. Bitton A, Peppercorn MA, Antonioli DA et al. Clinical, biological, and histologic parameters as predictors of relapse in ulcerative colitis. Gastroenterology 2001;120:13-20.
50. Sinclair TS, Brunt PW, Mowat NA. Nonspecific proctocolitis in northeastern Scotland: a community study. Gastroenterology 1983;85:1-11.
51. Hiwatashi N, Yamazaki H, Kimura M et al. Clinical course and long-term prognosis of Japanese patients with ulcerative colitis. Gastroenterol Jpn 1991;26:312-8.
52. Satsangi J, Silverberg MS, Vermeire S et al. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut 2006;55:749-53.
53. Wolters FL, van Zeijl G, Sijbrandij J et al. Internet-based data inclusion in a population-based European collaborative follow-up study of inflammatory bowel disease patients: description of methods used and analysis of factors influencing response rates. World J Gastroenterol 2005;11:7152-8.
54. Silverberg MS, Satsangi J, Ahmad T et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol 2005;19 (Suppl A):5-36.